Source: 헬스코리아뉴스(http://www.hkn24.com)
← Back to ListCompanyIn April of last year, Hanlim Pharmaceutical signed a joint research and development and investment agreement with emerging bio-venture company RudaCure for the dry eye disease treatment 'RCI001.' According to the company's announcement at the time, 'RCI001' showed faster promotion of tear secretion and corneal damage recovery compared to commercially available competing drugs, along with superior instillation compliance and safety. Through a mechanism that suppresses inflammatory activation, it exerts powerful anti-inflammatory and antioxidant effects to alleviate dry eye disease.
Source: 헬스코리아뉴스(http://www.hkn24.com) ← Back to List
Pharmaceutical companies line up to develop dry eye treatments
2021-12-30
Source: 헬스코리아뉴스(http://www.hkn24.com)